China Isotope & Radiation Corp
HKEX:1763
Net Margin
China Isotope & Radiation Corp
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CN |
C
|
China Isotope & Radiation Corp
HKEX:1763
|
3.9B HKD |
5%
|
|
| JP |
|
Hoya Corp
TSE:7741
|
6.2T JPY |
23%
|
|
| CH |
|
Alcon AG
SIX:ALC
|
35.1B CHF |
11%
|
|
| DK |
|
Coloplast A/S
CSE:COLO B
|
141.9B DKK |
16%
|
|
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
12.6B USD |
11%
|
|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
5.9B GBP |
8%
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
45.5B CNY |
40%
|
|
| CH |
|
Ypsomed Holding AG
SIX:YPSN
|
5.2B CHF |
12%
|
|
| US |
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
5.6B USD |
9%
|
|
| US |
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
5.1B USD |
17%
|
|
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
7T KRW |
-253%
|
China Isotope & Radiation Corp
Glance View
China Isotope & Radiation Corp. engages in the research, development, manufacturing and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications. The company is headquartered in Beijing, Beijing. The company went IPO on 2018-07-06. The firm also provides radiation sterilization services. The firm is also involved in the design, manufacture and installation of Gama ray irradiation devices. The firm opeartes its businesse mainly through four segments, including the Pharmaceuticals segment, the Radiological Products segment, the Irradiation segment and the Independent Medical Laboratory Services and Others segment, with the Pharmaceuticals segment as the core segment. The Pharmaceuticals segment is engaged in the development, manufacture and sale of radiopharmaceuticals, the Kit for Urea Breath Test and testing instruments, as well as in vitro immunodiagnostic reagents and boxes for imaging diagnosis and treatment.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on China Isotope & Radiation Corp's most recent financial statements, the company has Net Margin of 5.4%.
You don't have any saved screeners yet